Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Vertex Pharmaceuticals (VRTX) closed at $472.57 in the latest trading session, marking a -1.96% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.14% for the day. On the other hand, the Dow registered a loss of 0.01%, and the technology-centric Nasdaq decreased by 0.57%.
Shares of the drugmaker witnessed a gain of 2.9% over the previous month, trailing the performance of the Medical sector with its gain of 5.8%, and outperforming the S&P 500’s gain of 0.25%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company plans to announce its earnings on August 3, 2026. On that day, Vertex Pharmaceuticals is projected to report earnings of $4.85 per share, which would represent year-over-year growth of 7.3%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.23 billion, up 8.78% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $19.15 per share and a revenue of $13.06 billion, indicating changes of +4.08% and +8.83%, respectively, from the former year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts’ confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.04% decrease. At present, Vertex Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 25.17. This indicates a premium in contrast to its industry’s Forward P/E of 19.23.
We can additionally observe that VRTX currently boasts a PEG ratio of 1.93. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company’s expected earnings growth rate. As of the close of trade yesterday, the Medical – Biomedical and Genetics industry held an average PEG ratio of 1.57.
